New York-based mental health technology company Resilience Lab has acquired online psychiatric medication management platform Options MD. The transaction closed on September 28 and was announced on October 8, 2024.
Options MD is a telemedicine platform that provides personalized care for people suffering from severe and treatment-resistant mental illnesses.
Resilience Lab is an online mental healthcare platform that connects patients with therapists who specialize in depression, anxiety, attention-deficit/hyperactivity disorder, post-traumatic stress disorder, obsessive-compulsive disorder and more.
The acquisition allows Resilience to integrate Options MD’s medication management and psychotherapy offerings into its platform, giving patients with severe mental illness access to specialized clinicians for medication management. Resilience will also integrate Options MD’s proprietary clinical intake and AI decision support platform into its software suite, providing its therapists with AI-enabled diagnosis and treatment recommendations to assist them in creating an effective care plan.
Options MD’s workforce will be retained by Resilience Lab, and Options MD will operate as a business unit of Resilience Lab under its own brand. Financial terms of the deal were not disclosed.
According to data captured in the LevinPro HC database, this acquisition represents the 195th eHealth transaction of 2024, and the 35th in the telehealth specialty. There were 60 telehealth deals announced during 2023, and 55 announced during 2022.
